A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn
NCT ID: NCT03755128
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
17 participants
OBSERVATIONAL
2019-01-16
2023-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT03842189
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070
fFN Clinical Evaluation in Asymptomatic Women at High Risk for Preterm Birth
NCT01955148
PREPARE, Prematurity Reduction by Pre-eclampsia Care
NCT03073317
Identification of Early Predictors of Fetomaternal Hemorrhage
NCT01232387
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women and their offspring from current pregnancy
No intervention
No investigational drugs will be administered as part of the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No investigational drugs will be administered as part of the study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Research & Development, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Research & Development, LLC Clinical Trial
Role: STUDY_DIRECTOR
Janssen Research & Development, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Columbia University Medical Center
New York, New York, United States
University of Cincinnati
Cincinnati, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
UPMC
Pittsburgh, Pennsylvania, United States
University of Utah
Salt Lake City, Utah, United States
Liverpool Hospital
Liverpool, , Australia
The Royal Women's Hospital
Parkville, , Australia
Universitair Ziekenhuis Leuven
Leuven, , Belgium
The University of British Columbia
Vancouver, British Columbia, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
Centre Hospitalier Sainte Justine
Montreal, Quebec, Canada
Justus-Liebig-Universität Gießen, Kinderherzzentrum
Giessen, , Germany
Leiden University Medical Center
Leiden, , Netherlands
Hosp Clinic de Barcelona
Barcelona, , Spain
Hosp. Univ. San Cecilio
Granada, , Spain
Karolinska Universitetssjukhuset Huddinge
Stockholm, , Sweden
Queen Elizabeth Hospital
Edgbaston, , United Kingdom
University College London Hospitals NHSFT
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOM-M281-103
Identifier Type: OTHER
Identifier Source: secondary_id
CR109067
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.